Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Frank Sirotnak"'
Publikováno v:
Molecular Carcinogenesis. 41:150-163
Three unique variants of the CWR22 human prostate cancer xenograft model (CWR22LD1, LD2, and LD3) with a decrease in dependence on androgens were selected under noncastrate conditions, i.e., by outgrowth after transplantation into male NCR (AT) nu mi
Autor:
Owen A. O'Connor, Andrew D. Zelenetz, Eunice S. Wang, Frank Sirotnak, Malcolm A.S. Moore, Yuhong She
Publikováno v:
Leukemia & Lymphoma. 44:1027-1035
PDX (10-propargyl-10-deazaaminopterin) is a novel anti-folate with improved membrane transport and polyglutamylation in tumor cells. In prior studies, PDX exhibited enhanced efficacy over methotrexate (MTX) in lung and breast carcinoma xenografts. Be
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1492:531-536
cMOAT encodes an ATPase within the family of cMOAT/MRP ATPases that functions as an ATP dependent, multispecific anion transporter within the canalicular surface of hepatocytes that has pharmacologic significance. We describe here the cloning of a mu
Publikováno v:
ChemInform. 25
Publikováno v:
Journal of Biological Chemistry. 267:19986-19991
Studies are presented further characterizing a facilitative system transporting methotrexate (MTX) polyglutamates into lysosomes derived from S180 cells. Initial influx of [3H]MTX + G1 (MTX with 1 additional glutamyl residue) exhibited a slightly alk
Publikováno v:
Journal of Biological Chemistry. 267:15356-15361
Transport and metabolic turnover of methotrexate (MTX) polyglutamates were examined in lysosomes derived from S180 cells. These studies extend prior work from this laboratory (Barrueco, J. R., and Sirotnak, F. M. (1991) J. Biol. Chem 266, 11732-11737
Autor:
Scott R. Schlemmer, Frank Sirotnak
Publikováno v:
Journal of Biological Chemistry. 267:14746-14752
Earlier studies from our laboratory (Dembo, M., Sirotnak F. M., and Moccio, D. M. (1984) J. Membr. Biol. 78, 9-17) suggested that methotrexate (MTX) efflux from L1210 cells was mediated predominantly by an ATP-dependent, outwardly directed, mechanism
Autor:
Carol S. Portlock, Molly Patterson, Jill Mastrella, Steven M. Horwitz, Diane R. Mould, Barbara MacGregor-Cortelli, Frank Sirotnak, Rachel Hamelers, Owen A. O'Connor, Michael Saunders, Debra M. Sarasohn, Martin Fleisher, Andrew D. Zelenetz, Craig H. Moskowitz, Ellen Neylon, Venkatraman E. Seshan, Paul A. Hamlin
Purpose To determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in patients with lymphoma. Patients and Methods Pralatrexate, initially given at a dose of 135 mg/m2 on an every-other-week basis, was associated with stomatitis. A re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a43f77b284aa3ffff11fe0e7e1195aa7
https://europepmc.org/articles/PMC3651599/
https://europepmc.org/articles/PMC3651599/
Autor:
Michael Saunders, K Sweeney, Paul A. Hamlin, Ellen Neylon, Steven M. Horwitz, Frank Sirotnak, Martin Fleisher, Owen A. O'Connor, Diane R. Mould, Stephen B. Duffull
Publikováno v:
Clinical pharmacology and therapeutics. 86(2)
In a pralatrexate phase I study, patients displayed a high incidence of mucositis of grades 3 and 4. Preliminary evaluations of the pharmacokinetics of the drug and its association with mucositis suggested that pralatrexate exposure (area under the c
Autor:
Debra M. Sarasohn, Andrew D. Zelenetz, Martin Fleischer, Otila Dumetrescu, Barbara MacGregor-Cortelli, Craig H. Moskowitz, Diane R. Mould, Steven M. Horwitz, Ariela Noy, Paul A. Hamlin, Frank Sirotnak, Owen A. O'Connor, David J. Straus, Ellen Neylon, Carol S. Portlock
Publikováno v:
British journal of haematology. 139(3)
T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma